US SEC Filings Daily Market Digest — September 09, 2026

09-09-2026

C3.ai, Inc. reported results for the fiscal first quarter ended July 31, 2026, showing a 25.5% decline in total revenue to $52.4M from $70.3M in the prior-year quarter. Subscription revenue fell 18.5% to $49.2M, and professional services revenue dropped 67.9% to $3.2M. Net loss narrowed to $92.8M from $116.8M, driven by a 15.9% reduction in operating expenses to $114.9M, though the company remained unprofitable. Cash and cash equivalents more than doubled sequentially to $136.4M, and operating cash flow turned positive at $2.1M versus a $33.5M use of cash a year ago.

• · North America revenue declined 33.8% YoY to $42.6M from $64.4M
• · Europe, Middle East and Africa revenue increased 59.9% YoY to $9.0M from $5.6M
• · Asia Pacific revenue was $0.3M, up from $0.02M
• · Rest of World revenue was $0.5M, up from $0.2M
• · Total operating expenses decreased 24.0% YoY to $114.9M from $151.3M
• · General & administrative expense increased 8.2% YoY to $26.1M from $24.1M
• · Restructuring charge of $0.7M was incurred in Q1 FY27 vs. none in Q1 FY26
• · Weighted-average diluted shares rose 14.5% to 155.0 million from 135.4 million
• · Net loss per share improved to ($0.60) from ($0.86)
• · Stock-based compensation expense (including amounts in cost of revenue) totaled $59.2M in Q1 FY27, down 8.6% from $64.8M in Q1 FY26

09-09-2026

Food Culture Inc. voluntarily filed a Form 8-K on September 8, 2026, solely to provide a clear public reference for its current corporate identity, security identifiers, capitalization, and contact information. The filing reflects the company’s name change from Golden Star Enterprises Ltd. to Food Culture Inc., updates its principal executive office address to Rego Park, New York, and discloses 45,089,630 common shares outstanding with no preferred shares. The company is not subject to SEC reporting requirements and does not intend this submission to alter its reporting status.

• · Current CUSIP: 38119W305; prior (superseded) CUSIP: 38119W206
• · Trading symbol: FCUL; Market: OTC Link (OTC Markets Group) – OTCID tier
• · Reporting standard: OTC Markets Alternative Reporting Standard
• · Company incorporated in Delaware on September 13, 1993; standing active
• · Fiscal year end: December 31
• · Transfer agent: VStock Transfer, LLC (Woodmere, NY)
• · Website: https://foodcultureinc.com; investor relations email: [email protected]
• · No securities registered under Section 12(b); not subject to Sections 13(a) or 15(d)
• · Principal business: development and marketing of premium spirits and ready-to-drink beverages

09-09-2026

Signet Jewelers reported Q2 FY2027 results with same-store sales growth of 2.2% and adjusted operating income rising to $107.2M from $85.4M a year ago. However, total sales were essentially flat at $1,528.1M vs $1,535.1M in Q2 FY2026, and the company guided Q3 same-store sales as low as -1.0%. Management raised full-year adjusted EPS guidance by over 10% to $10.45-$12.15, announced a $125M accelerated share repurchase program, and expanded the share repurchase authorization by $385M to $700M.

• · Q3 FY2027 sales guidance of $1.37B to $1.41B, with same-store sales ranging from -1.0% to +2.0%
• · Full-year FY2027 adjusted EBITDA guidance raised to $730M-$800M from prior $665M-$745M
• · New consumer credit agreement with Bread Financial extends through December 2035, includes profit-sharing and signing bonus
• · Approximately $60M-$80M net revenue reduction expected from James Allen brand transition
• · Annual tax rate guidance of 23%-25%
• · Planned capital expenditures of $150M-$180M
• · Net square footage decrease of low single digit for the year
• · Q2 FY2027 included $0.86 per share negative impact from asset impairments net of taxes
• · Dividend of $0.35 per share declared for Q3 FY2027, payable November 20, 2026
• · After completion of anticipated ASR, approximately $575M in share repurchase authorization would remain

09-09-2026

Orion180 Insurance Group Inc. filed Amendment No. 1 to its S-1 registration statement for an initial public offering of 20,000,000 shares of Class A common stock, with an estimated IPO price range of $15.00 to $17.00 per share. The company has applied to list on the Nasdaq Global Select Market under the symbol 'OIG'. Post-offering, founder and CEO Kenneth Gregg will hold 93.9% of voting power (93.4% if underwriters' option is exercised in full), making the company a 'controlled company' exempt from certain Nasdaq governance rules.

• · The company is an emerging growth company and has elected to comply with reduced public company reporting requirements.
• · The company will have two classes of common stock post-offering: Class A (one vote per share) and Class B (ten votes per share, convertible to Class A).
• · The offering is subject to completion and the registration statement must be declared effective by the SEC before securities can be sold.
• · The company's principal executive offices are located in Melbourne, Florida.
• · The company uses non-GAAP financial measures including Consolidated adjusted EBITDA and Consolidated adjusted EBITDA margin.
• · The filing includes a glossary of insurance, reinsurance, and financial terms.
• · The company has developed a proprietary smart home IoT device called Auto Water Turn-off System (AWTOS).

09-09-2026

Can-Fite BioPharma announced a peer-reviewed case report showing that its drug Namodenoson improved decompensated cirrhosis in a patient, resolving ascites and regressing esophageal varices, and successfully bridged the patient to liver transplantation after approximately 28 months of treatment. However, the clinical improvements occurred despite continued deterioration in hepatic synthetic function, and the findings are based on a single-patient observation, limiting generalizability.

• · Namodenoson is a highly selective agonist of the A3 adenosine receptor (A3AR), which is highly expressed in inflammatory and pathological cells.
• · Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, a Phase 2b trial for MASH, and has concluded a Phase 2a study in pancreatic cancer.
• · Namodenoson has Orphan Drug Designation in the U.S. and Europe and Fast Track Designation by the FDA as a second-line treatment for HCC.
• · The patient underwent successful orthotopic liver transplantation from a deceased donor in January 2026.
• · During treatment, ascites resolved allowing discontinuation of diuretic therapy, and follow-up endoscopy showed only minimal residual esophageal varices.
• · The article was published in the Japanese Journal of Gastroenterology and Hepatology.

09-09-2026

Destination XL Group reported Q2 fiscal 2026 sales of $111.6 million, down 3.4% YoY, with comparable sales down 3.5%. Net income was $2.0 million ($0.04/diluted share) vs. a net loss of $(0.3) million in Q2 2025, boosted by a $4.6 million tariff refund. However, total cash and investments fell sharply to $20.1 million from $33.5 million a year ago, and the Board is recommending stockholders vote against the proposed merger with FullBeauty, citing FullBeauty's declining performance and potential negative equity value.

• · Merchandise margin increased 340 basis points, largely due to the $4.6M tariff refund; occupancy costs rose 70 basis points from deleveraging.
• · Comparable sales improved sequentially through the quarter: May (-5.7%), June (-2.8%), July (-1.9%).
• · SG&A expenses decreased $1.8M, driven by lower incentive-based compensation and favorable healthcare costs.
• · Marketing costs remained flat at 6.1% of sales, with full-year guidance of ~5.8%.
• · The Board now recommends voting against the FullBeauty merger, citing FullBeauty's declining performance, increased debt, and potential negative equity value.
• · Transaction-related costs rose to $1.8M (vs. $0.1M) due to professional fees for the proposed merger.

09-09-2026

Sunbelt Rentals reported record Q1 FY27 results with total revenue up 11.2% to $3,115M and rental revenue up 12.5% to $2,927M, driven by strong North America Specialty growth (+25.3%) and General Tool growth (+7.4%). However, the UK segment saw a rental revenue decline of 1.4% to $209M, and adjusted EBITDA margin contracted to 42.2% from 43.2% in the prior year. The company raised full-year guidance across all key metrics and announced a shift to quarterly dividends.

• · The Aries acquisition contributed ~100 bps to total rental revenue growth and ~300 bps to Specialty rental revenue growth.
• · FIFA World Cup contributed ~250 bps to total rental revenue growth.
• · Average fleet age increased to 52 months from 50 months year-over-year.
• · Net leverage was 1.8x, within the target range of 1x-2x.
• · Excess availability under senior secured credit facility was $3,750M.
• · Weighted average cost of credit facilities is approximately 5%.
• · The company opened 13 greenfield locations in Q1.
• · Return on investment (TTM) remained flat at 14.6%.
• · General Tool dollar utilization remained flat at 47%.
• · UK adjusted operating profit margin improved 10 bps to 8.3% despite revenue decline.
• · The quarterly dividend of $0.30 replaces the previous semi-annual UK distribution framework.
• · Guidance raised: Total revenue growth 6%-9% (from 4.5%-7.5%), Rental revenue growth 7%-10% (from 5%-8%), Adjusted EBITDA $4.92B-$5.12B (from $4.85B-$5.05B), Net rental equipment CapEx $2.4B-$2.8B (from $2.05B-$2.45B).

09-09-2026

Pyxis Oncology announced updated Phase 1 data for micvotabart pelidotin (MICVO) in 2L+ recurrent/metastatic head and neck squamous cell carcinoma, showing a confirmed ORR of 36% (12/33) and a disease control rate of 94% (31/33). Median PFS was 6.2 months and 12-month OS probability was 79%, with median OS not reached. However, safety data showed high rates of treatment-related adverse events (91.4% all-grade, 54.3% Grade ≥3) and notable peripheral neuropathy (40% all-grade, 17.1% Grade 3), though no new safety signals were observed.

• · Median treatment duration was 120 days (range 21-470).
• · Peripheral neuropathy days to onset: median 82 days for Grade 1/2, 166 days for Grade 3.
• · TRAEs leading to discontinuation: 1 ocular, 1 muscle weakness, 3 peripheral neuropathy.
• · Prior EGFRi subgroup: cORR 28% (5/18) vs 47% (7/15) in no prior EGFRi; mPFS 5.0 vs 8.8 months.
• · Prior novel EGFRi subgroup (n=5): cORR 40%, mPFS 5.8 months.
• · HPV+ oropharyngeal subgroup: cORR 35%, mPFS 6.2 months; HPV-unrelated: cORR 38%, mPFS 5.9 months.
• · Prior taxane subgroup: cORR 35%, mPFS 6.2 months; no prior taxane: cORR 40%, mPFS 4.9 months.
• · No new safety signals were observed; tolerability consistent with other auristatin-based ADCs.

09-09-2026

Incannex Healthcare Inc. provided a corporate update on September 9, 2026, highlighting the start of patient dosing in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea and the grant of a U.S. composition patent for IHL-42X expiring in 2040. The company reported a strong cash position of approximately $70 million with no debt, including over A$11.2 million in non-dilutive capital received in 2026. However, the press release contains no new financial results or comparative performance data, and the PSX-001 program for generalized anxiety disorder lacks a defined timeline for the next clinical milestone.

• · The U.S. composition and methods of treatment patent for IHL-42X was granted on June 25, 2026, with baseline expiry of July 9, 2040.
• · Incannex received A$6.0 million refund from Australian R&D Tax Incentive in June 2026 and an additional A$5.1 million refund in August 2026.
• · IHL-42X received Fast Track designation from the FDA in December 2025.
• · In the RePOSA Phase 2 study, reductions in apnea-hypopnea index of up to 83% were observed in individual patients.
• · PSX-001 has an open U.S. Investigational New Drug application for the PsiGAD2 Phase 2b dose-comparison study.
• · The company has presented a refined development strategy for PSX-001 to the UK MHRA through a scientific advice meeting.

09-09-2026

Daedalus Special Acquisition Corp. (DSAC) announced a non-binding Letter of Intent to acquire HubX, a Turkish consumer AI company, through a business combination that will take HubX public on Nasdaq. HubX has received a $75M investment commitment from Point72 in connection with the deal. The transaction is subject to definitive agreements, due diligence, and regulatory approvals, and no financial terms of the combination itself have been disclosed.

• · HubX was established in 2022 and is based in Turkiye.
• · HubX is structured as a technology hub with autonomous in-house studios and a central platform.
• · HubX was the first company to get an AI generated output from Google's TPU.
• · The letter of intent is non-binding and the transaction is subject to execution of definitive agreements, completion of due diligence, shareholder and regulatory approvals, and other customary closing conditions.
• · Daedalus Special Acquisition Corp. is a SPAC (blank check company) focused on building a diversified portfolio of profitable AI-powered consumer apps.

09-09-2026

Core & Main, Inc. reported Q2 FY26 net sales of $2,145M, up 2.5% YoY from $2,093M, and net income attributable to the company of $144M, up 7.5% from $134M. For the first half of FY26, net sales rose 1.3% to $4,055M and net income increased 7.7% to $252M. However, storm drainage product sales declined 0.3% in Q2 and 2.9% in the first half, and the company's share repurchase activity accelerated significantly, with $257M in buybacks during the first six months versus $47M a year ago.

• · Cash and cash equivalents increased to $312M as of August 2, 2026, from $220M at February 1, 2026.
• · Total assets grew to $6,709M from $6,085M over the same period.
• · Long-term debt increased to $2,432M from $2,124M, reflecting $929M in new borrowings and $617M in repayments during H1 FY26.
• · Operating cash flow improved to $144M in H1 FY26 from $111M in H1 FY25.
• · Capital expenditures rose to $32M in H1 FY26 from $23M in H1 FY25.
• · The company repurchased and retired 3,685,511 Class A shares in Q2 FY26 alone, compared to 121,835 in Q2 FY25.
• · Diluted EPS for Q2 FY26 was $0.77, up from $0.70 in Q2 FY25.
• · Gross profit margin was 26.7% in Q2 FY26, slightly down from 26.8% in Q2 FY25.
• · Selling, general and administrative expenses as a percentage of net sales improved to 14.0% in Q2 FY26 from 14.4% in Q2 FY25.

09-09-2026

Perma-Pipe International Holdings reported strong Q2 FY2026 results with net sales up 24.4% YoY to $59.6M and net income attributable to common stock increasing to $2.5M ($0.31 per diluted share) from $0.9M in the prior-year quarter. However, gross margin declined to 29.2% from 30.1% due to increased materials and logistics costs and ramp-up costs at the new Ohio facility, and the quarter included a $3.9M charge for an uncollectible receivable. Backlog grew to $142.3M, supported by over $67M in new orders, and the company secured a new $90M global credit facility with JPMorgan.

• · General and administrative expenses increased to $11.9M from $10.0M YoY, including a $3.9M charge for an uncollectible receivable and $0.5M in Ohio start-up costs, partially offset by lower personnel costs.
• · Selling expenses were $1.3M, compared to $1.2M in the prior-year quarter.
• · Net interest expense increased to $0.5M from $0.4M YoY due to incremental borrowings.
• · Adjusted income before taxes (non-GAAP) was $8.3M for Q2 FY2026 vs. $4.9M in Q2 FY2025; for the six-month period, it was $12.5M vs. $12.3M.
• · Income tax expense decreased to $0.6M from $1.5M YoY; effective tax rate dropped to 16% from 54% due to a $1.6M discrete tax benefit.
• · Cash provided by operating activities was $7.2M in Q2 FY2026 and $13.3M in the first six months of FY2026, compared to $1.3M used in the prior-year six-month period.
• · Total debt increased to $36.1M at July 31, 2026 from $32.5M at January 31, 2026.
• · The new JPMorgan credit facility includes a $75.0M revolving line (with $30.0M for letters of credit) and a $14.0M term loan, plus up to $50.0M incremental capacity; $23.0M was drawn on the revolver at closing.
• · Subsequent to quarter-end, the company repaid the mortgage on its Alberta, Canada plant using proceeds from the new facility.
• · Backlog was $142.3M at July 31, 2026, up from $136.5M at April 30, 2026 and $121.6M at January 31, 2026.
• · New orders in Q2 included significant oil and gas awards in MENA and Canada, the first critical-cooling infrastructure award in MENA, and continued backlog growth at the Ohio facility.
• · For the six-month period, net income attributable to common stock declined 25.1% to $4.3M from $5.8M, and income from operations declined 19.7% to $8.9M from $11.1M.
• · The company's effective tax rate can vary meaningfully due to changes in the mix of income and loss across jurisdictions.

09-09-2026

Gloo Holdings reported Q2 2026 revenue of $46.6 million, up 188% YoY, exceeding guidance of $44.0 million and analyst consensus. Net loss narrowed to $21.2 million from $44.1 million in the prior-year period. However, the company remains unprofitable on a GAAP basis, with Adjusted EBITDA still negative at -$8.3 million, though it showed a third consecutive quarter of sequential improvement. Management expects Adjusted EBITDA profitability in Q4 2026.

• · Q2 2026 revenue was more than double the prior year and exceeded guidance of $44.0M.
• · Net loss improved 52% YoY to $21.2M, but remains substantial on an absolute basis.
• · Adjusted EBITDA improved sequentially for the third consecutive quarter, from -$11.5M in Q1 2026 to -$8.3M in Q2 2026.
• · The company extended its $13.2M senior secured loan by one year to April 2028.
• · Five strategic acquisitions were completed since public market debut: XRI Global, Westfall Group, Enterprisemarketdesk, remaining stake in Midwestern Interactive, and Cedarstone.
• · Over 30 customers with $1M+ annual contract value, including one >$10M customer.
• · 40+ universities served; guidance for Q3 2026 revenue is $55M (+69% YoY), with adjusted EBITDA guidance of -$3.5M.
• · Fiscal year 2026 revenue guidance raised to $200M, more than double the prior year.
• · No reconciliation of forward Adjusted EBITDA to GAAP provided (unreasonable efforts exception).

09-09-2026

Independence Realty Trust (IRT) and Centerspace announced a definitive all-stock merger agreement to create a leading middle-market multifamily REIT with a total enterprise value of approximately $8.1 billion and over 44,000 apartment homes across 17 states. The transaction is expected to be approximately 5% accretive to 2027 core FFO per share with $24 million in identified annualized synergies, primarily from G&A overlaps. However, the merger introduces integration risk and requires shareholder approval, with closing expected as early as the end of Q4 2026.

• · The combined company will have 58% pro-forma NOI from Sun Belt, 27% from Midwest, and 15% from Mountain West.
• · No single market accounts for more than 11% of pro-forma NOI.
• · Roughly 80% of pro-forma NOI comes from markets in the top quartile for projected population growth.
• · The combined company's G&A load as a % of assets (37 bps) is well below the REIT sector average of 61 bps.
• · IRT has a track record of exceeding synergy targets in prior mergers (Trade Street 2015, Steadfast 2021).
• · The transaction is expected to qualify as a tax-free reorganization for US federal income tax purposes.
• · Centerspace has one mortgage maturing on January 1, 2027, which is not expected to be assumed.
• · The average remaining term of the planned debt assumptions is 10 years.
• · The combined company expects to maintain its BBB investment-grade rating from Fitch and S&P.
• · The exchange ratio is 3.8 IRT shares per Centerspace share.
• · Centerspace will pay a stubbed cash dividend of $0.09 per share in the closing quarter.

09-09-2026

Century Therapeutics appointed Joseph Truitt to its Board of Directors. The company also provided updates on its pipeline: CNTY-813 remains on track for an IND submission in Q4 2026, and CNTY-308 is anticipated to enter the clinic in 2026. No financial results or negative performance metrics were disclosed.

• · Joseph Truitt currently serves as CEO and board member of iECURE, Inc., chairman of Larimar Therapeutics, and board member of Code Biotherapeutics.
• · Truitt previously led BioSpecifics Technologies until its acquisition by Endo International in December 2020, and held senior roles at Achillion Pharmaceuticals before its acquisition by Alexion Pharmaceuticals in January 2020.
• · Truitt served as a Captain in the United States Marine Corps and holds an MBA from Saint Joseph's University and a BS from La Salle University.
• · CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes (T1D).
• · CNTY-308 is a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy for B-cell-mediated diseases.
• · Both programs are engineered with Century's Allo-Evasion™ 5.0 platform.

09-09-2026

Indivior PLC filed an amended S-4 registration statement on September 9, 2026, detailing its merger with Supernus Pharmaceuticals, Inc. Under the merger, each Supernus share will be exchanged for 1.5401 Indivior shares, with Indivior to be renamed Supernus, Inc. The Indivior board unanimously recommends stockholders vote for the share issuance and adjournment proposals, while the merger is subject to stockholder approvals, HSR clearance, Nasdaq listing, and other customary conditions.

• · Indivior's common stock trades on Nasdaq Global Select Market under ticker 'INDV'; Supernus shares trade on Nasdaq Global Market under 'SUPN'.
• · Indivior has more than 25 years of experience in addiction medicine, specializing in long-acting injectable medications for opioid use disorder.
• · Supernus focuses on CNS diseases including ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, and cervical dystonia.
• · No appraisal rights are available for either Indivior or Supernus shareholders under Delaware law.
• · Record date for both special meetings is September 4, 2026.
• · Indivior equity awards (PSUs and RSUs) will be converted or adjusted; Supernus equity awards will be assumed by Indivior and converted using the exchange ratio of 1.5401.

09-09-2026

InMed Pharmaceuticals Inc. filed an S-4/A registration statement on September 9, 2026, in connection with its proposed merger with Mentari (the 'Merger'). The filing details that InMed is expected to become a shell company upon closing, subjecting the Combined Company to heightened SEC reporting requirements, including a mandatory Form 10 filing, a 12-month S-3 ineligibility, a 60-day S-8 filing delay, and a three-year 'ineligible issuer' status. While the Merger aims to create strategic value, InMed shareholders will face substantial dilution and reduced ownership in the Combined Company, and the filing highlights significant conflicts of interest among directors and executive officers who may benefit from retention bonuses, accelerated equity vesting, and continued compensation.

• · InMed is expected to be deemed a shell company after the Merger, triggering shell company business combination rules.
• · The Combined Company will be ineligible to use Form S-3 for 12 full calendar months after closing.
• · The Combined Company must wait at least 60 calendar days after closing to file a Form S-8 for equity plans or awards.
• · The Combined Company will be an 'ineligible issuer' for three years following closing, preventing incorporation by reference in Form S-1 filings and use of free writing prospectuses.
• · Affiliates of Mentari receiving securities in the Merger (Rule 145(c) securities) will be deemed underwriters and may not be included in the anticipated Form S-1 resale registration statement unless sold in a fixed price offering.
• · Rule 144(i)(2) will limit public resale of Rule 145(c) securities and other restricted/control securities until one year after Form 10 information is filed.
• · Directors and executive officers of InMed and Mentari have interests in the Merger that differ from other shareholders, including retention bonuses, accelerated vesting of InMed Options, severance payments, and continued indemnification rights.
• · Current Mentari Board members will continue as directors of the Combined Company and be eligible for non-employee director compensation under InMed's policy.
• · InMed shareholders will experience substantial dilution of their ownership interests without commensurate benefit if the Combined Company fails to realize anticipated strategic and financial benefits.

09-09-2026

SDR Drone, Inc. (formerly Hallmark Venture Group, Inc.) filed a belated 8-K disclosing that previously issued financial statements for FY2024 and FY2025, plus interim 2025 quarters, should no longer be relied upon due to material misstatements. The restatement increased net loss by $1.57M for FY2025 and $0.83M for FY2024, driven by errors in convertible note accounting, revenue recognition, and vendor accruals. Management also disclosed material weaknesses in internal controls, including lack of segregation of duties and no independent audit committee, though a new Audit Committee was established in June 2026.

• · Restated accumulated deficit at Dec 31, 2025: $5,315,165 (previously $3,745,941)
• · Restated accumulated deficit at Dec 31, 2024: $3,922,221 (previously $3,096,015)
• · Restated basic and diluted net loss per share for FY2024: $(0.56)
• · Material weaknesses: no segregation of duties, no independent audit committee, no documented ICFR assessment
• · Company failed to file Item 4.02 8-K within 4 business days of determinations (April 27 and May 27, 2026); filing is belated
• · Corrections for FY2024 also include discontinued operations presentation for Jubilee Intel, LLC and 1-for-500 reverse stock split adjustment (not errors)

09-09-2026

See Remarks Schenk Chris was awarded 62,829 Stock Option.

• · See Remarks Schenk Chris was awarded 62,829 Stock Option
• · See Remarks Schenk Chris was awarded 62,829 Stock Option

09-09-2026

Lesaka Technologies filed its annual 10-K for the fiscal year ended June 30, 2026, reporting total assets of $699.3M, up from $651.5M in the prior year. The company grew cash and cash equivalents to $81.4M from $76.5M and expanded finance loans receivable to $103.8M from $74.1M. However, inventory declined to $20.1M from $23.6M, and settlement assets fell to $18.5M from $27.1M, while total liabilities increased to $415.0M from $396.3M.

• · The company's accumulated other comprehensive loss improved to -$166.3M from -$185.6M.
• · Non-controlling interest was reduced to $0 from $6.8M.
• · Short-term credit facilities decreased to $20.7M from $24.5M.
• · Long-term borrowings increased to $194.6M from $188.8M.
• · Operating lease right-of-use assets more than doubled to $20.2M from $9.7M.
• · The company had a public float of approximately $252.1M as of Dec 31, 2025.
• · Auditor is KPMG, Inc. based in Johannesburg, South Africa.

09-09-2026

CooperCompanies reported Q3 FY2026 revenue of $1.066B, up 1% YoY with 1% organic growth, and non-GAAP diluted EPS of $1.15, up 4% YoY. However, CooperVision revenue was flat YoY at $717.0M, with declines in the Americas (-2%) and Asia Pacific (-5%), while CooperSurgical grew 2% to $349.2M. Free cash flow surged 66% to $273.0M, and the company repurchased $339.1M of stock. GAAP EPS of $2.24 was boosted by a $307.2M discrete tax benefit from a UK tax examination, compared to $0.49 in the prior year.

• · CooperVision Americas revenue declined 2% YoY to $281.6M; Asia Pacific declined 5% YoY to $126.0M.
• · CooperVision Sphere category revenue declined 1% organically YoY to $353.2M.
• · Non-GAAP gross margin declined 60 bps YoY to 67% due to higher manufacturing costs and unfavorable FX.
• · GAAP operating margin improved to 21% from 17% YoY, driven by lower operating expenses and prior-year write-offs.
• · Interest expense decreased 15.4% YoY to $21.5M due to lower rates and lower average debt.
• · Q4 FY2026 guidance: total revenue $1.057B-$1.080B (0-2% organic growth); CVI revenue expected to decline 0-2% organically.
• · Fiscal 2026 guidance: total revenue $4.229B-$4.252B (2-3% organic growth); non-GAAP diluted EPS $4.51-$4.55.
• · Company reaffirmed long-term free cash flow objective exceeding $2.2B for FY2026-2028.

09-09-2026

Centerspace (CSR) and Independence Realty Trust (IRT) announced a definitive all-stock merger agreement to create a combined multifamily REIT with a total enterprise value of approximately $8.1 billion and over 44,000 apartment homes across 17 states. The transaction is expected to be approximately 5% accretive to 2027 core FFO per share on a leverage-neutral basis, with approximately $24 million in identified annualized synergies. However, the merger requires shareholder approval and lender consents, with closing expected as early as the end of Q4 2026, and involves planned asset sales of approximately $140 million to de-lever the combined balance sheet.

• · Combined company will retain the Independence Realty Trust name and trade under ticker IRT on NYSE.
• · Each Centerspace common share and OP unit will convert into 3.8 IRT shares/units.
• · Transaction expected to qualify as tax-free reorganization for US federal income tax purposes.
• · Sun Belt represents 58% of pro-forma NOI; Midwest 27%; Mountain West 15%.
• · No single market accounts for more than 11% of pro-forma NOI.
• · Combined company's G&A load as percentage of assets falls to 37 bps, below REIT sector average of 61 bps.
• · IRT expects to maintain its quarterly dividend of $0.18 per share post-closing; Centerspace will pay a stubbed cash dividend of $0.09 per share in closing quarter.
• · Centerspace has one mortgage maturing on January 1, 2027, which will not be assumed and will be repaid on or before closing.
• · Average remaining term of assumed secured debt is 10 years.
• · Both boards have unanimously approved the transaction.
• · IRT's total shareholder return since IPO has outperformed non-gateway peers.

09-09-2026

Amazon elected Kevin R. Mandia, a cybersecurity veteran and former CEO of Mandiant, to its Board of Directors on September 8, 2026. He was also appointed to the Audit and Security Committees. In connection with his election, he received a restricted stock unit award of 4,086 shares vesting over three years. Additionally, the filing discloses that Kristin Mandia, the sister-in-law of Mr. Mandia, is an Amazon employee with an annual salary of $185,000 and a 103-share RSU award, with compensation stated as consistent with peers.

• · Kevin Mandia served as CEO of Mandiant from June 2016 to July 2024 and as a director from February 2016 to September 2022.
• · Mandiant was acquired by Google LLC in September 2022.
• · Kevin Mandia co-founded Ballistic Ventures and has been a General Partner since June 2024.
• · He founded Armadin, Inc. in September 2025 and serves as its CEO.
• · The RSU award for Kevin Mandia vests in three equal annual installments beginning November 15, 2027.
• · Kristin Mandia's RSU award vests over 1.9 years.
• · The indemnification agreement for directors was filed as an exhibit to Amendment No. 1 to the Company's Registration Statement on Form S-1 (Registration No. 333-23795), filed April 21, 1997.

09-09-2026

First Majestic Silver Corp. filed a Form 6-K with the SEC on September 9, 2026, attaching a news release dated the same day. The filing is a routine foreign private issuer report under the Exchange Act.

09-09-2026

Opus Genetics reported positive interim clinical data from Cohort 1 of its Phase 1/2 trial for OPGx-BEST1 in BEST1-related retinal diseases. All five participants showed clinically meaningful improvements in visual function, with a favorable safety profile and no serious adverse events. The company has advanced to a higher-dose Cohort 2, which has been over-enrolled to eight participants, and aligned with the FDA on potential pivotal trial endpoints.

• · The company aligned with the FDA on a potential pivotal endpoint based on ≥3 dB microperimetry improvement in ≥5 prespecified loci, in conjunction with a patient-reported outcome in a randomized, controlled trial.
• · BCVA, LLVA and CS may also be acceptable endpoints.
• · The company also aligned with the FDA on Phase 3 and commercial manufacturing requirements, which it expects to complete in early 2027.
• · The company currently expects to begin planning for participant dosing in the Phase 3 clinical trial in 2027.
• · Cohort 2 dosing expected to be complete in Q4 2026, with topline three-month data expected in Q2 2027.

09-09-2026

Milton C. Ault III and Ault & Company, Inc. filed Amendment No. 18 to their Schedule 13D, disclosing beneficial ownership of 318,429,036 Class A shares (65.9% of outstanding Class A shares) and 317,418,715 Class A shares (65.7%), respectively, as of September 4, 2026. The filing details the conversion of various convertible preferred stocks and warrants, with a conversion price of $0.1763 per share. Other insiders (Horne, Nisser, Cragun) each hold less than 1% of Class A shares.

• · The conversion price for Series C, G, and H Preferred Stock is the greater of $0.10 per share or 105% of the 10-day VWAP; for this filing, a conversion price of $0.1763 was used.
• · Class B Shares carry 10 votes per share, while Class A Shares carry 1 vote per share, affecting voting power percentages.
• · Stock options awarded to officers have a strike price of $3.60 per share, expire July 30, 2035; 50% vested on May 6, 2026, and the remaining 50% vest monthly over 24 months starting June 1, 2026.
• · Ault & Company holds sole/shared power to vote and dispose of 317,418,715 Class A Shares; Mr. Ault has sole power over 1,010,321 shares and shared power over 317,418,715 shares.

09-09-2026

Standard BioTools Inc. (LAB) filed an S-4/A proxy statement/prospectus for its all-stock merger with Treeline Biosciences, where Treeline will be the accounting acquirer and Standard BioTools will become 'Treeline Biosciences Holdings, Inc.' The merger implies an equity value of $2.5 billion for Treeline and $460 million for Standard BioTools, with former Standard BioTools stockholders expected to hold approximately 16% of the combined company and Treeline stockholders approximately 84%. Concurrently, Standard BioTools will divest its mass cytometry business to Multiplex Bio Inc. for an undisclosed amount, and must wind down any remaining legacy businesses if not sold by the S-4 effectiveness date. The merger is subject to stockholder approval and other conditions, with the special meeting scheduled for 2026.

• · Exchange ratio estimated at 11.6997 shares of Standard BioTools Common Stock per share of Treeline Capital Stock, subject to adjustment based on actual capitalizations and Parent Net Cash at closing.
• · Merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
• · Standard BioTools will assume Treeline's 2021 Equity Incentive Plan and all outstanding Treeline options and warrants, with adjustments to exercise prices and share counts based on the exchange ratio.
• · The Merger is accounted for as a reverse recapitalization, with Treeline as the accounting acquirer; historical financial statements of Treeline will become the combined company's historical financials.
• · Standard BioTools must use commercially reasonable efforts to divest or wind down its mass cytometry and microfluidics businesses (Legacy Businesses) if not sold by the S-4 effectiveness date.
• · The Mass Cytometry Purchase Agreement with Multiplex Bio was entered into on July 28, 2026.
• · The Special Meeting will be held entirely virtually, with the date left blank in the filing.
• · The Merger is not conditioned on the closing of the Mass Cytometry Divestiture, but is expected to close substantially concurrently.
• · Risk factors are detailed beginning on page 42 of the proxy statement/prospectus.

09-09-2026

GIVBUX, INC. (GBUX) filed its 10-Q for the quarter ended June 30, 2026, reporting a net loss of $548,094 for the three months and $755,170 for the six months, a significant improvement from the prior year's losses of $6,104,831 and $6,631,650 respectively. Revenue declined sharply to $34,264 (Q3) and $90,170 (six months) from $55,803 and $121,826 in the prior year periods, while operating expenses decreased but remained high relative to revenue. The company ended the period with only $17,976 in cash and a stockholders' deficit of $5,073,302.

• · Total operating expenses for Q3 2026 were $316,224, down from $553,950 in Q3 2025, a 42.9% decrease.
• · Professional fees were $199,863 in Q3 2026, up from $182,343 in Q3 2025.
• · Interest expense increased to $281,478 in Q3 2026 from $269,382 in Q3 2025.
• · The company issued 1,000,000 shares of Series C Preferred Stock in exchange for due to related party.
• · Common stock issued for conversion of convertible notes totaled 66,723,766 shares in Q2 2026.
• · Stockholders' deficit improved to $5,073,302 at June 30, 2026 from $8,939,703 at June 30, 2025.
• · Net cash used in operating activities for the six months was $213,261, compared to $597,237 in the prior year period.
• · The company had no cash paid for interest or taxes in either period.

09-09-2026

MapLight Therapeutics, Inc. filed an S-1 registration statement for an initial public offering (IPO) on September 9, 2026. The company is a clinical-stage biopharmaceutical company focused on CNS disorders, with lead candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis. While the company reported positive Phase 2 topline results for ML-007C-MA in July 2026, it has incurred substantial losses since inception and anticipates needing significant additional financing to achieve its goals.

• · MapLight was incorporated in November 2018 as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019.
• · Principal executive offices are located at 800 Chesapeake Drive, Redwood City, California 94063.
• · The company has a limited operating history and no history of commercializing products.
• · ML-007C-MA received Fast Track designation from the FDA for Alzheimer's disease psychosis in December 2025.
• · Topline results from the IRIS Phase 2 trial for ML-004 were announced in June 2026.
• · The company expects to report topline results from the VISTA Phase 2 trial for ML-007C-MA in Alzheimer's disease psychosis in the second half of 2027.
• · The company intends to engage with the FDA in an end-of-Phase 2 meeting for ML-004 to determine next steps, after which it will evaluate potential strategic collaborations and/or funding alternatives.
• · The company is subject to various U.S. federal, state and foreign healthcare laws and regulations.

09-09-2026

Ares Management entities filed a Schedule 13D disclosing beneficial ownership of approximately 23.7% of Hornbeck Offshore Services, Inc. (formerly Helix Energy Solutions Group Inc.) common stock, representing 61,738,413 shares. The ownership arose from the September 1, 2026 merger closing, where Legacy Hornbeck shares and warrants were converted into Hornbeck common stock. The Reporting Persons stated they may engage in discussions regarding extraordinary corporate transactions, including a potential take-private, but currently have no definitive plans.

• · The merger closed on September 1, 2026; Legacy Hornbeck common stock was converted at an exchange ratio of 10.27167 shares of Hornbeck common stock per share.
• · Jones Act Warrants have an exercise price of $0.00001 per share and are subject to ownership restrictions in the Issuer's certificate of incorporation.
• · The Reporting Persons may acquire additional shares or sell holdings, and may enter into financial instruments affecting economic exposure.
• · Antony P. Ressler generally has veto authority over board decisions of Ares Partners Holdco LLC, which disclaims beneficial ownership.

09-09-2026

Form 4 ownership filing; the structured EDGAR document could not be retrieved for automated parsing.

09-09-2026

President of North America Reddout Mark had withheld for taxes 5,049 Common Stock at $30.07 (~$152K). Reddout Mark holds 119,263 shares after the transaction.

• · President of North America Reddout Mark had withheld for taxes 5,049 Common Stock at $30.07 (~$152K)

09-09-2026

EVP & Chief Mfg and Supply Cha Brosius Mark sold 46 Common Stock at $361.23 (~$16.6K). Brosius Mark holds 812 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · EVP & Chief Mfg and Supply Cha Brosius Mark sold 46 Common Stock at $361.23 (~$16.6K)
• · EVP & Chief Mfg and Supply Cha Brosius Mark sold 23 Common Stock at $350.20 (~$8.05K)

09-09-2026

COO Huffaker Michael bought 36,580 Common Stock at $9.64 (~$353K). Huffaker Michael holds 139,560 shares after the transaction.

• · COO Huffaker Michael bought 21,160 Common Stock at $9.11 (~$193K)
• · COO Huffaker Michael bought 21,718 Common Stock at $9.35 (~$203K)
• · COO Huffaker Michael bought 36,580 Common Stock at $9.64 (~$353K)

09-09-2026

President, CEO Weingarten Tomer sold 38,759 Class A Common Stock at $19.79 (~$767K). Weingarten Tomer holds 1,801,827 shares after the transaction.

• · President, CEO Weingarten Tomer sold 38,759 Class A Common Stock at $19.79 (~$767K)

09-09-2026

Director Tang Andrew R was awarded 85,000 Ordinary Shares. Tang Andrew R holds 310,000 shares after the transaction.

• · Director Tang Andrew R was awarded 85,000 Ordinary Shares

09-09-2026

Premium Catering (Holdings) Ltd filed a Form 6-K with the SEC on September 9, 2026, incorporating by reference its interim financial results for the six-month period ended December 31, 2025. The filing is signed by CFO Ka Hei Wong and will be incorporated into the company's registration statement. No specific financial figures or performance metrics are disclosed in the cover filing itself.

• · The filing is a Form 6-K (Report of Foreign Private Issuer) for the month of September 2026.
• · The company indicates it files annual reports under Form 20-F.
• · The interim results cover the six-month period ended December 31, 2025.
• · The financial statements are provided as Exhibit 99.1 to the filing.

09-09-2026

Eldorado Gold Corporation filed a Form 6-K with the SEC for September 2026, attaching a news release dated September 8, 2026. The filing is a routine foreign issuer report and does not contain any financial results or material operational updates.

• · The filing is a Form 6-K for the month of September 2026.
• · The attached news release (Exhibit 99.1) is dated September 8, 2026.
• · The registrant files annual reports under Form 40-F.

09-09-2026

Evotec SE announced that its biologics division, Evotec Biologics, has advanced a U.S. Department of War-funded antibody program targeting orthopoxvirus into Phase 1 clinical studies. The press release was issued on September 9, 2026, and filed as a Form 6-K with the SEC. No financial details or performance metrics were disclosed in this filing.

• · The antibody program is funded by the U.S. Department of War.
• · The program targets orthopoxvirus, which includes smallpox and monkeypox viruses.
• · The Phase 1 clinical studies represent the next stage of development for this program.

09-09-2026

SK hynix Inc. responded to a Korea Exchange disclosure inquiry regarding media reports that it is pursuing the sale of an ownership stake in its Chongqing, China packaging plant, reportedly valued at approximately Won 4 trillion. The company clarified that while it is reviewing various measures to strengthen its packaging business competitiveness, no matters have been determined as of the report date. SK hynix will make a further disclosure either when specific details are confirmed or within three months of the report date (September 9, 2026).

• · The disclosure inquiry was made by the Korea Exchange on August 10, 2026.
• · The company's response was furnished on September 9, 2026, within the three-month disclosure window.
• · The company explicitly states 'no matters have been determined' regarding the potential sale.
• · The company references a prior Form 6-K filing on August 10, 2026, regarding the same inquiry.

09-09-2026

Postal Realty Trust closed on the acquisition of a 72-property portfolio leased to the USPS from entities partially owned by CEO Andrew Spodek for $27.75 million. The purchase price consisted of $25.75 million in cash and $2.0 million in OP Units, with Mr. Spodek receiving approximately $11.88 million of the cash consideration and all of the OP Units. The acquisition was approved by a special committee of independent directors, and the portfolio is 100% occupied with 148,374 net leasable square feet.

09-09-2026

AITX announced via an 8-K filing that its subsidiary RAD is experiencing expanding orders for its RIO, ROSA, and SARA products at the start of Q3. The filing includes a press release as an exhibit but provides no specific financial figures or quantitative details on the order expansion. The announcement is purely qualitative and forward-looking, with no comparative performance data to assess growth or decline.

• · The press release is titled 'AITX's RAD Opens Q3 With Expanding Orders Across RIO, ROSA and SARA'.
• · The filing is furnished under Item 8.01 and is not deemed 'filed' for SEC liability purposes.
• · No financial metrics, order values, or period-over-period comparisons are provided in the 8-K.

09-09-2026

Baker Hughes CEO Lorenzo Simonelli will present at the Barclays 2026 CEO Energy-Power Conference on September 9, 2026, discussing the company's positioning at the intersection of energy, industrial, and infrastructure markets and the integration of its recent acquisition of Chart Industries. The company will also provide updated fiscal-year 2026 financial guidance incorporating Chart. No specific financial figures or performance metrics were disclosed in this filing.

• · Presentation at Barclays 2026 CEO Energy-Power Conference in New York at approximately 8:35 A.M. Eastern Time.
• · Updated fiscal-year 2026 financial guidance incorporating Chart will be presented.
• · The presentation is furnished as Exhibit 99.1 and includes non-GAAP financial measures.

09-09-2026

Magnum Ice Cream Co B.V. (MICC) disclosed a series of share purchases on Euronext, CBOE DXE, and Turquoise Europe from September 3 to September 8, 2026, for its Long Term Incentive Plans. Over the four trading days, the company acquired a total of 1,179,328 ordinary shares at an aggregate cost of approximately €19.67 million, with average daily purchase prices ranging from €16.45 to €16.96 per share. The purchases were spread across venues, with CBOE DXE receiving the largest allocation each day, followed by Euronext and Turquoise Europe.

• · The daily purchase volume declined from 308,104 shares on 3 September to 260,455 shares on 8 September, a decrease of approximately 15.5%.
• · Average daily purchase price fell from €16.96 on 3 September to €16.54 on 8 September, a decline of about 2.5%.
• · CBOE DXE consistently received the highest number of shares each day, ranging from 134,706 to 163,869 shares.
• · Turquoise Europe received the smallest allocation each day, with volumes between 26,550 and 27,520 shares.

09-09-2026

Black Pearl Equities completed its tender offer for all outstanding shares of Selectis Health, Inc. at $5.75 per share in cash, with 2,789,027 shares tendered (90.93% of outstanding shares). The acquisition will proceed via a short-form merger under Utah law, converting remaining shares to the same cash price, making Selectis an indirect wholly owned subsidiary. The transaction represents a full acquisition of the company, with no negative financial metrics reported in the filing.

• · Tender offer expired at 5:00 p.m. New York City time on August 31, 2026.
• · Merger will be completed without a stockholder vote under Section 16-10a-1108 of the Utah Revised Business Corporation Act.
• · Selectis operates eight properties in Arkansas and Oklahoma, providing skilled nursing, assisted living, and independent living services.
• · Reimbursement sources include Medicare, Medicaid, and private pay arrangements.
• · Information agent: Laurel Hill Advisory Group (toll-free (844) 305-2265, email [email protected]).
• · Depositary: Broadridge Corporate Issuer Solutions, LLC.

09-09-2026

Unite Acquisition 2 Corp. filed an 8-K on September 9, 2026, including audited consolidated financial statements of Blue Laser Fusion, Inc. for the years ended December 31, 2025 and 2024, as Exhibit 99.1. The filing indicates a business combination transaction between the SPAC and Blue Laser Fusion, a fusion energy company. The financial statements show the company's financial position and results, but no specific revenue or net income figures are provided in the excerpt; the auditor's opinion is unqualified.

• · Auditor: PCAOB-registered firm, served as auditor since 2026.
• · Audit location: San Francisco, California.
• · Audit report date: June 11, 2026.
• · Financial statements include balance sheets, statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders’ deficit, and cash flows.
• · No opinion expressed on internal control over financial reporting.

09-09-2026

KT Corp disclosed monthly purchases of its own shares under a KRW 250 billion trust arrangement, totaling 4,480,551 shares for KRW 249,999,959,500 (approximately $187.5 million) over the period from April to August 2026. The monthly purchase amounts varied, with the highest in July (KRW 58.9 billion) and the lowest in August (KRW 37.5 billion), reflecting a decline in the final month.

• · The trust arrangement has a total amount of KRW 250,000,000,000, and the cumulative purchases reached 100.0% of that amount by August 31, 2026.
• · Monthly purchase quantities ranged from 709,256 shares (August) to 1,100,000 shares (July).
• · The purchase ratio of the total trust amount peaked at 23.6% in July and fell to 15.0% in August.